Pegzilarginase - Aeglea BioTherapeutics

Drug Profile

Pegzilarginase - Aeglea BioTherapeutics

Alternative Names: AEB-1102; AERase; Co-ArgI-PEG - Aeglea Biotherapeutics; Co-ArgI-PEG modified human arginase I - Aeglea Biotherapeutics; Optimised human arginase I - Aeglea Biotherapeutics; PEG-arginase - Aeglea Biotherapeutics; Pegarginase - Aeglea Biotherapeutics

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aeglea Biotherapeutics
  • Class Antineoplastics; Enzymes; Polyethylene glycols; Ureohydrolases
  • Mechanism of Action Arginase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperargininemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hyperargininemia
  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours
  • Preclinical Non-small cell lung cancer

Most Recent Events

  • 20 Dec 2017 Phase-II clinical trials in Hyperargininemia (In adolescents, In children, In adults) in USA (IV) (NCT03378531)
  • 07 Nov 2017 Preclinical trials in Non-small cell lung cancer (Combination therapy) in USA (IV)
  • 16 Oct 2017 Aeglea Biotherapeutics and Merck plans a phase I/II trial for Small cell lung cancer (Combination therapy, Second-line therapy or greater) in USA (IV) in the first quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top